Q4 2013 13F Holders as of 12/31/2013
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
24M
-
Shares change
-
-9.92K
-
Total reported value, excl. options
-
$2.49B
-
Value change
-
-$533K
-
Put/Call ratio
-
0.86
-
Number of sells
-
-1
-
Price
-
$103.53
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q4 2013
117 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q4 2013.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24M shares
of 49.6M outstanding shares and own 48.37% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP LLC (5.69M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.95M shares), FMR LLC (2.87M shares), LORD, ABBETT & CO. LLC (1.49M shares), VANGUARD GROUP INC (1.33M shares), Citadel Advisors LLC (649K shares), FRANKLIN RESOURCES INC (622K shares), BlackRock Fund Advisors (544K shares), State Street Corp (536K shares), and FEDERATED INVESTORS INC /PA/ (484K shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.